Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Nika Vučković

PhD Student


Phone: +49 6221 42 3822


Scientific CV

Since July 2020
PhD student, Immunotherapy and Immunoprevention, DKFZ, Heidelberg

Mar 2018 - Dec 2018
Master´s thesis research at University of Toronto, Toronto, Canada

Aug 2017 - Jan 2018
Erasmus exchange to Chalmers University of Technology, Gothenburg, Sweden

2016 - 2019
MSc Molecular Biology, University of Zagreb, Croatia

2012 - 2016
BSc Molecular Biology, University of Zagreb, Croatia

Research project

Identification of HLA-presented HPV epitopes on cervical intraepithelial neoplasia (CIN) cells for therapeutic vaccine design
Cervical cancer is caused by persistent infection with high-risk human papillomaviruses (HPV). Virtually every sexually active individual contracts a high-risk HPV infection over their lifetime, with most infections eradicated by the immune system on the strength of an effective T-cell response. However, by dysregulating the antigen processing machinery (APM), HPV interferes with T-cell recognition of infected/transformed cells. The Riemer lab has shown that such dysregulation increases as the tumor stage progresses, therefore it is plausible that more HPV epitopes are HLA-presented on HPV-positive cells in precursor lesions (such as cervical intraepithelial neoplasia; CIN) than in fully developed cancer. Moreover, the microenvironment in CIN lesions is less immunosuppressive so therapeutic vaccination in this setting is promising. The aim of this project is to identify and validate HPV16-derived T-cell epitopes presented on CIN cells with the goal of defining a set of epitopes for an efficacious therapeutic HPV vaccine.

Resulting Publications

to top
powered by webEdition CMS